ZA201303175B - Human anti-tau antibodies - Google Patents
Human anti-tau antibodiesInfo
- Publication number
- ZA201303175B ZA201303175B ZA2013/03175A ZA201303175A ZA201303175B ZA 201303175 B ZA201303175 B ZA 201303175B ZA 2013/03175 A ZA2013/03175 A ZA 2013/03175A ZA 201303175 A ZA201303175 A ZA 201303175A ZA 201303175 B ZA201303175 B ZA 201303175B
- Authority
- ZA
- South Africa
- Prior art keywords
- human anti
- tau antibodies
- tau
- antibodies
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39175110P | 2010-10-11 | 2010-10-11 | |
EP10013494 | 2010-10-11 | ||
PCT/IB2011/002786 WO2012049570A1 (en) | 2010-10-11 | 2011-10-11 | Human anti-tau antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA201303175B true ZA201303175B (en) | 2021-05-26 |
Family
ID=43602869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2013/03175A ZA201303175B (en) | 2010-10-11 | 2013-04-30 | Human anti-tau antibodies |
Country Status (23)
Country | Link |
---|---|
US (6) | US8940272B2 (pt) |
EP (1) | EP2627672B1 (pt) |
JP (2) | JP2014503178A (pt) |
CN (1) | CN103339146B (pt) |
AU (1) | AU2011315181B2 (pt) |
BR (1) | BR112013008765B8 (pt) |
CA (1) | CA2813493C (pt) |
CY (1) | CY1120951T1 (pt) |
DK (1) | DK2627672T3 (pt) |
EA (1) | EA031698B1 (pt) |
ES (1) | ES2686550T3 (pt) |
HR (1) | HRP20181320T8 (pt) |
IL (1) | IL225670B (pt) |
LT (1) | LT2627672T (pt) |
MX (1) | MX345092B (pt) |
NZ (1) | NZ609984A (pt) |
PL (1) | PL2627672T3 (pt) |
PT (1) | PT2627672T (pt) |
SG (1) | SG189174A1 (pt) |
SI (1) | SI2627672T1 (pt) |
TR (1) | TR201812636T4 (pt) |
WO (1) | WO2012049570A1 (pt) |
ZA (1) | ZA201303175B (pt) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
NZ609984A (en) | 2010-10-11 | 2015-05-29 | Biogen Idec Internat Neuroscience Gmbh | Human anti-tau antibodies |
EP2670434B1 (en) * | 2011-01-31 | 2018-12-26 | Tau Bio-Logic Corp. | Treatment of tauopathies |
UA114902C2 (uk) * | 2011-12-20 | 2017-08-28 | Янссен Байотек, Інк. | Виділене антитіло, яке зв'язує парний спіральний філамент-тау (псф-тау), та фармацевтична композиція, що містить таке антитіло |
MY171473A (en) * | 2012-07-03 | 2019-10-15 | Univ Washington | Antibodies to tau |
WO2014016737A1 (en) * | 2012-07-24 | 2014-01-30 | Pfizer Inc. | Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof |
CA2882034C (en) | 2012-08-16 | 2019-10-29 | Ipierian, Inc. | Methods of treating a tauopathy |
US20140056901A1 (en) * | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
LT2935326T (lt) * | 2012-12-21 | 2020-12-10 | Biogen Ma Inc. | Žmogaus antikūnai prieš tau baltymą |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
JP6568514B2 (ja) * | 2013-03-15 | 2019-08-28 | エーシー イミューン エス.エー. | 抗タウ抗体及び使用方法 |
PL3007726T3 (pl) * | 2013-06-10 | 2021-01-11 | Ipierian, Inc. | Metody leczenia tauopatii |
GB201312226D0 (en) * | 2013-07-08 | 2013-08-21 | Adx Neurosciences | Improved antibodies |
MX2016006356A (es) * | 2013-11-27 | 2016-10-28 | Ipierian Inc | Metodos de tratamiento de una tauopatia. |
DK3083680T3 (da) | 2013-12-20 | 2020-03-16 | Hoffmann La Roche | Humaniserede anti-Tau(pS422)-antistoffer og fremgangsmåder til anvendelse |
WO2015122922A1 (en) | 2014-02-14 | 2015-08-20 | Ipierian, Inc. | Tau peptides, anti-tau antibodies, and methods of use thereof |
ZA201608812B (en) * | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
BR112016030183A2 (pt) * | 2014-06-26 | 2017-11-14 | Janssen Vaccines & Prevention Bv | anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos |
AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
TW202136296A (zh) * | 2014-06-27 | 2021-10-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
JP6679582B2 (ja) * | 2014-09-30 | 2020-04-15 | ワシントン・ユニバーシティWashington University | タウの動態測定 |
US10098973B2 (en) | 2014-10-10 | 2018-10-16 | National Research Council Of Canada | Anti-tau antibody and uses thereof |
RU2020126237A (ru) * | 2014-11-19 | 2020-12-01 | Аксон Ньюросайенс Се | Гуманизированные тау-антитела при болезни альцгеймера |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
CA2977648C (en) | 2015-02-24 | 2024-01-02 | Rpeptide, Llc | Anti-tau antibodies |
JO3576B1 (ar) | 2015-02-26 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لـ tau واستخداماتها |
WO2016164530A1 (en) * | 2015-04-07 | 2016-10-13 | University Of Maryland, College Park | Compositions and methods for high throughput protein sequencing |
MA44955A (fr) | 2015-06-05 | 2019-03-20 | Ac Immune Sa | Anticorps anti-tau et leurs méthodes d'utilisation |
CN107810196B (zh) | 2015-06-24 | 2021-11-05 | 豪夫迈·罗氏有限公司 | 人源化的抗-Tau(pS422)抗体和使用方法 |
EP3319984A1 (en) | 2015-07-06 | 2018-05-16 | UCB Biopharma SPRL | Tau-binding antibodies |
JO3711B1 (ar) * | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
CN105388302A (zh) * | 2015-12-22 | 2016-03-09 | 中国医学科学院输血研究所 | 一种人免疫球蛋白制品中Tau蛋白抗体含量的检测方法 |
WO2017157961A1 (en) | 2016-03-14 | 2017-09-21 | Biogen International Neuroscience Gmbh | Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins |
HUE060258T2 (hu) | 2016-05-02 | 2023-02-28 | Prothena Biosciences Ltd | Tau immunterápia |
CU24538B1 (es) | 2016-05-02 | 2021-08-06 | Prothena Biosciences Ltd | Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7 |
CA3022515A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2017211827A1 (en) | 2016-06-07 | 2017-12-14 | Biogen International Neuroscience Gmbh | Methods for treating alzheimer's disease |
CA3027561A1 (en) | 2016-07-12 | 2018-01-18 | H. Lundbeck A/S | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | 新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用 |
WO2018017370A1 (en) * | 2016-07-20 | 2018-01-25 | Anahit Ghochikyan | Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
US20190330318A1 (en) | 2016-07-25 | 2019-10-31 | Biogen Ma Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
WO2018031361A2 (en) | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination therapy |
CA3036264A1 (en) | 2016-09-08 | 2018-03-15 | Regenerative Research Foundation | Bi-functional anti-tau polypeptides and use thereof |
MX2019006334A (es) | 2016-12-07 | 2019-08-01 | Genentech Inc | Anticuerpos antitau y métodos de uso. |
CA3045294A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
EP3562840A1 (en) | 2016-12-16 | 2019-11-06 | Biogen MA Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
EP3583123A1 (en) * | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
JOP20180014A1 (ar) | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه |
JOP20180021A1 (ar) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
WO2018178080A1 (en) * | 2017-03-28 | 2018-10-04 | Janssen Vaccines & Prevention B.V. | Methods for detection of tau protein aggregation modulating compounds |
CN110494446A (zh) | 2017-03-28 | 2019-11-22 | 基因泰克公司 | 治疗神经退行性疾病的方法 |
KR20190133191A (ko) * | 2017-03-28 | 2019-12-02 | 얀센 백신스 앤드 프리벤션 비.브이. | 타우에 특이적으로 결합하는 결합 분자 |
BR112019022906A2 (pt) | 2017-05-02 | 2020-05-26 | Prothena Biosciences Limited | Anticorpos que reconhecem tau |
MX2019015071A (es) * | 2017-06-16 | 2020-02-13 | Bristol Myers Squibb Co | Composiciones y metodos para tratar tauopatias. |
KR20200044023A (ko) | 2017-08-22 | 2020-04-28 | 바이오젠 엠에이 인코포레이티드 | 항-베타 아밀로이드 항체를 함유하는 약제학적 조성물 |
SG11202002575UA (en) | 2017-10-02 | 2020-04-29 | Merck Sharp & Dohme | Chromane monobactam compounds for the treatment of bacterial infections |
JOP20200074A1 (ar) | 2017-10-16 | 2020-04-30 | Eisai R&D Man Co Ltd | أجسام مضادة ضد tau واستخداماتها |
EP3720490A1 (en) * | 2017-12-04 | 2020-10-14 | Janssen Vaccines & Prevention B.V. | Binding molecules that specifically bind to tau |
EP3724232A4 (en) | 2017-12-14 | 2021-12-15 | The University of Ottawa | EXOSOME PACKAGING AND TARGETED AUTOPHAGY |
WO2019161384A1 (en) * | 2018-02-19 | 2019-08-22 | New York University | Tau single domain antibodies |
NL2020520B1 (en) * | 2018-03-02 | 2019-09-12 | Labo Bio Medical Invest B V | Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders |
US20210002358A1 (en) * | 2018-03-05 | 2021-01-07 | Linda Barone | Anti-phf-tau antibodies and uses thereof |
CA3090356A1 (en) * | 2018-03-11 | 2019-09-19 | Koorosh Shahpasand | Conformation-independent antibodies against neurotoxic tau proteins |
CN112543648A (zh) | 2018-07-31 | 2021-03-23 | 伊莱利利公司 | 组合疗法 |
JP2022509372A (ja) | 2018-10-29 | 2022-01-20 | バイオジェン・エムエイ・インコーポレイテッド | 血液脳関門輸送の促進のためのヒト化され安定化されたfc5バリアント |
PE20211777A1 (es) * | 2018-11-08 | 2021-09-08 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
PE20212324A1 (es) | 2019-03-03 | 2021-12-14 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
WO2020201828A1 (en) | 2019-04-05 | 2020-10-08 | Tauc3 Biologics Limited | Anti-tauc3 antibodies and uses thereof |
CN114641490B (zh) | 2019-08-06 | 2023-06-06 | 新旭生技股份有限公司 | 结合至病理性tau种类的抗体及其用途 |
CN114502781A (zh) * | 2019-09-20 | 2022-05-13 | 纳维再生科技股份有限公司 | 个人化癌症免疫治疗 |
TW202216759A (zh) | 2020-06-25 | 2022-05-01 | 美商默沙東藥廠 | 靶向絲胺酸413經磷酸化之tau之高親和力抗體 |
US20240101654A1 (en) * | 2020-12-29 | 2024-03-28 | Neurimmune Ag | Human anti-tau antibodies |
KR20240049296A (ko) | 2021-08-27 | 2024-04-16 | 제넨테크, 인크. | 타우 병증을 치료하는 방법 |
WO2023041805A1 (en) | 2021-09-20 | 2023-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
CA3239708A1 (en) | 2021-12-03 | 2023-06-08 | Aubin MICHALON | Novel potency assay for antibody-based drugs and useful means therefor |
WO2023178049A1 (en) | 2022-03-14 | 2023-09-21 | Genentech, Inc. | Predicting neurodegenerative diseases based on speech analyses |
WO2023250326A1 (en) | 2022-06-21 | 2023-12-28 | Genentech, Inc. | Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses |
WO2024026471A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
WO2024026472A2 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
CN116948025B (zh) * | 2023-09-14 | 2024-04-02 | 北京凯祥弘康生物科技有限公司 | 一种抗Tau蛋白的抗体 |
CN117106081B (zh) * | 2023-09-28 | 2024-05-07 | 北京凯祥弘康生物科技有限公司 | 一种抗nfl蛋白的捕获抗体 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
EP0362371A4 (en) | 1988-04-15 | 1990-10-24 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
DE68921982D1 (de) | 1988-06-14 | 1995-05-04 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
CA2078689C (en) | 1990-03-20 | 2003-02-11 | Sherie L. Morrison | Chimeric antibodies with receptor binding ligands in place of their constant region |
JPH09506761A (ja) | 1990-11-09 | 1997-07-08 | ステファン ディー.ギリーズ | サイトカインの免疫複合体 |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
WO1993008302A1 (en) * | 1991-10-25 | 1993-04-29 | Itt Automotive Europe Gmbh | Monoclonal antibodies directed against the microtubule-associated protein tau |
EP0746609A4 (en) * | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
CA2149326C (en) | 1992-11-13 | 2007-04-17 | Mitchell E. Reff | Fully impaired consensus kozak sequences for mammalian expression |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
AU690092B2 (en) | 1992-12-14 | 1998-04-23 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications |
CA2178212C (en) | 1993-12-21 | 2011-06-14 | Marc Vandermeeren | Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications |
US6121003A (en) | 1994-07-29 | 2000-09-19 | Innogentics N.V. | Monoclonal antibodies specific for an epitope of phosphorylated tau, and their use |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
AU5508798A (en) * | 1996-11-19 | 1998-06-10 | Trustees Of The University Of Pennsylvania, The | Diagnostic and therapeutic reagents for alzheimer's disease |
ATE296356T1 (de) | 1997-03-14 | 2005-06-15 | Biogen Idec Inc | Methode zur spezifischen integration von genen in säugetierzellen durch homologe rekombination, und vektoren zu deren durchführung |
EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
AU1631700A (en) | 1998-11-23 | 2000-06-13 | Idec Pharmaceuticals Corporation | Tumor antigen-specific antibody-gp39 chimeric protein constructs |
US20040110938A1 (en) | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
CN1306272C (zh) | 2000-11-17 | 2007-03-21 | 罗切斯特大学 | 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法 |
IL157142A0 (en) | 2001-01-29 | 2004-02-08 | Idec Pharma Corp | Modified antibodies and methods of use |
WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
EP1425694A2 (en) * | 2001-08-03 | 2004-06-09 | Medical Research Council | Method of identifying a consensus sequence for intracellular antibodies |
DE60219925T2 (de) | 2001-08-24 | 2008-01-17 | Universität Zürich | Methode zur induzierung neurofibrillärer tangles in transgenen tieren |
US20030157641A1 (en) | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
EP1535930B1 (en) | 2002-08-14 | 2010-10-06 | Mitsubishi Chemical Medience Corporation | Antibody specific to central nervous system tau protein |
US20060240485A1 (en) | 2003-04-24 | 2006-10-26 | Universitat Zurich | Method of monitoring immunotherapy |
NZ545776A (en) | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
WO2005080986A1 (en) | 2004-02-18 | 2005-09-01 | University Of Iowa Research Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
JP4730584B2 (ja) * | 2004-12-06 | 2011-07-20 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
US7083854B1 (en) | 2005-05-10 | 2006-08-01 | Cornell Research Foundation, Inc. | Fibers from polymer nanoclay nanocomposites by electrospinning |
CA2657953A1 (en) | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
WO2007068105A1 (en) | 2005-12-12 | 2007-06-21 | Robarts Research Institute | Method of diagnosing amyotrophic lateral sclerosis |
US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
PL2099826T3 (pl) * | 2007-01-05 | 2014-04-30 | Univ Zuerich | Przeciwciało przeciwko beta-amyloidowi i jego zastosowania |
EP2344452A4 (en) * | 2008-09-16 | 2012-03-14 | Univ Fraser Simon | SELECTIVE GLYCOSIDASE HEMMER AND ITS USE |
US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
EA032675B1 (ru) * | 2009-06-10 | 2019-07-31 | Нью-Йорк Юниверсити | Способ и композиции для лечения болезни альцгеймера и других таупатий |
WO2011053565A2 (en) | 2009-10-29 | 2011-05-05 | Biomedical Sciences Research Centre "Alexander Fleming" | Compositions and methods for detecting a tauopathy |
AU2011311516B2 (en) | 2010-10-07 | 2015-06-11 | Ac Immune S.A. | Phosphospecific antibodies recognising Tau |
NZ609984A (en) | 2010-10-11 | 2015-05-29 | Biogen Idec Internat Neuroscience Gmbh | Human anti-tau antibodies |
EP2670434B1 (en) | 2011-01-31 | 2018-12-26 | Tau Bio-Logic Corp. | Treatment of tauopathies |
EP2701743A4 (en) | 2011-04-27 | 2015-08-19 | Univ Northwestern | SELECTIVE ANTIBODIES FOR TAU PATHOLOGICAL DIMERS AND PRE-FIBRILLARY TAU PATHOLOGICAL OLIGOMERS AND THEIR USE IN THE TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES |
US20120323214A1 (en) | 2012-05-16 | 2012-12-20 | Totada R Shantha | Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis |
LT2935326T (lt) | 2012-12-21 | 2020-12-10 | Biogen Ma Inc. | Žmogaus antikūnai prieš tau baltymą |
-
2011
- 2011-10-11 NZ NZ609984A patent/NZ609984A/en unknown
- 2011-10-11 BR BR112013008765A patent/BR112013008765B8/pt active IP Right Grant
- 2011-10-11 EP EP11797115.0A patent/EP2627672B1/en active Active
- 2011-10-11 DK DK11797115.0T patent/DK2627672T3/en active
- 2011-10-11 SI SI201131553T patent/SI2627672T1/sl unknown
- 2011-10-11 JP JP2013532287A patent/JP2014503178A/ja active Pending
- 2011-10-11 TR TR2018/12636T patent/TR201812636T4/tr unknown
- 2011-10-11 AU AU2011315181A patent/AU2011315181B2/en active Active
- 2011-10-11 SG SG2013023775A patent/SG189174A1/en unknown
- 2011-10-11 EA EA201390453A patent/EA031698B1/ru unknown
- 2011-10-11 CA CA2813493A patent/CA2813493C/en active Active
- 2011-10-11 PT PT11797115T patent/PT2627672T/pt unknown
- 2011-10-11 PL PL11797115T patent/PL2627672T3/pl unknown
- 2011-10-11 ES ES11797115.0T patent/ES2686550T3/es active Active
- 2011-10-11 CN CN201180048980.7A patent/CN103339146B/zh active Active
- 2011-10-11 WO PCT/IB2011/002786 patent/WO2012049570A1/en active Application Filing
- 2011-10-11 MX MX2013003879A patent/MX345092B/es active IP Right Grant
- 2011-10-11 US US13/271,118 patent/US8940272B2/en active Active
- 2011-10-11 US US13/878,839 patent/US20130295021A1/en not_active Abandoned
- 2011-10-11 LT LTEP11797115.0T patent/LT2627672T/lt unknown
-
2013
- 2013-04-10 IL IL225670A patent/IL225670B/en active IP Right Grant
- 2013-04-30 ZA ZA2013/03175A patent/ZA201303175B/en unknown
-
2014
- 2014-11-04 US US14/532,531 patent/US9605059B2/en active Active
-
2016
- 2016-02-01 JP JP2016016975A patent/JP6300842B2/ja active Active
-
2017
- 2017-02-08 US US15/427,733 patent/US20180002409A1/en not_active Abandoned
-
2018
- 2018-08-16 HR HRP20181320TT patent/HRP20181320T8/hr unknown
- 2018-09-12 US US16/128,978 patent/US20190233506A1/en not_active Abandoned
- 2018-11-01 CY CY181101135T patent/CY1120951T1/el unknown
-
2020
- 2020-09-17 US US17/023,814 patent/US20210238265A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181320T8 (hr) | Ljudska anti-tau protutijela | |
HRP20180952T1 (hr) | Anti-dll3 antitijelo | |
HK1216538A1 (zh) | 人類微管相關蛋白抗體 | |
ZA201209004B (en) | Anti-fgfr2 antibodies | |
GB201000467D0 (en) | Antibodies | |
IL221371A0 (en) | Anti-lrp6 antibodies | |
IL221288A0 (en) | Therapeutic methods using anti-cd200 antibodies | |
RS59769B1 (sr) | Antitela protiv humanog cd38 | |
HUE040213T2 (hu) | Anti-TIM antitest | |
IL225667A0 (en) | A new antigen | |
HK1194388A1 (zh) | 抗缺刻蛋白 抗體 | |
PL2603528T3 (pl) | Przeciwciała Fab-glikozylowane | |
GB201020738D0 (en) | Antibodies | |
GB201002238D0 (en) | Antibodies | |
ZA201302459B (en) | Antibodies | |
GB201007957D0 (en) | Antibody | |
IL226635B (en) | Human anti-sod1 antibodies | |
GB201020751D0 (en) | Antibodies | |
GB201005062D0 (en) | Antibodies | |
HUE048721T2 (hu) | Humán CD38 elleni ellenanyagok | |
GB201017780D0 (en) | Antibody |